CD8A and neoplasm: Despite the debated CMV existence, some clinical trials have reported that targeting pp65 CMV immunodominant epitope with one injection of autologous tumour lysate-pulsed DC immediately invoked a CMV-specific CD8+ T cell response in GBM patients,93,94 revealing CMV viral antigen as an attractive exogenous immunotherapeutic target.73